Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment
1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared ...
Tag: foundayo
Orforglipron (Foundayo) expands oral treatment options for weight management
1. Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food or timing ...
